Αποτελέσματα Αναζήτησης
Risks with the use of FFP include potential for initial worsening of angioedema (specifically in hereditary angioedema due to its bradykinin content), viral transmission, delayed administration time, allergic/transfusion reactions, and volume overload .
5 Μαρ 2024 · Benefits of fresh frozen plasma. Treatment options for bradykinin-mediated angioedema range from a C1-esterase inhibitor concentrate (C1-INH), which contain a working version of the protein of the same name, to medications that block the action of kallikrein or bradykinin.
11 Αυγ 2020 · This is the first time the successful treatment of hereditary angioedema with FFP has been reported from Pakistan. In the absence of targeted therapy in most LMICs, FFP is an alternative therapeutic option for the acute management of HAE.
3 Φεβ 2016 · Fresh frozen plasma (FFP) is one treatment option for acute bradykinin-induced AE with airway compromise. The first report of its successful use was in hereditary AE in 1969 [6]. Subsequent case reports have demonstrated the effectiveness of FFP (given within 45 minutes to 12 hours) for both HAE and non-HAE [7, 8].
a Department of Emergency and Critical Care Medicine, Sri Gokulam Hospitals and Research Institute, Salem. b Department of Emergency Medicine, Christian Medical College and Hospital, Vellore. c Department of Forensic Medicine and Toxicology, Srinivas Institute of Medical Sciences and Research Centre, Mangalore. d Department of Internal Medicine, Chennai Medical College Hospital and Research ...
13 Απρ 2017 · Although not US Food and Drug Administration approved for acute treatment, fresh-frozen plasma (FFP) also may be used for ACEi-induced and other bradykinin-mediated angioedema. FFP provides volume replacement and is effective in most cases of bradykinin-mediated angioedema with onset of symptom relief in approximately 30 to 90 min .
12 Οκτ 2019 · Plasma (fresh-frozen) remains the only available effective on-demand treatment for acute HAE in many countries. FFP is effective and safe, but time-to-resolution is slower and adverse events are more frequent than published data on targeted therapies.
